Differential effect of carbamazepine and oxcarbazepine on excitatory synaptic transmission in rat hippocampus. 2008

Michela Giustizieri, and Marta Armogida, and Nicola Berretta, and Mauro Federici, and Silvia Piccirilli, and Nicola B Mercuri, and Robert Nistico
Laboratory of Experimental Neurology, Fondazione Santa Lucia IRCCS, Rome, Italy.

In this study, we have compared the effects of two structurally related compounds carbamazepine (CBZ) and oxcarbazepine (OXC), both in current use for the treatment of epilepsy and bipolar disorder, on fast excitatory transmission in rat hippocampal slices. Using electrophysiological recordings, we have investigated the effects of CBZ and OXC on repetitive action potential discharge of CA1 pyramidal neurons demonstrating that both compounds produced firing inhibition with similar IC(50) values. Moreover, we show that bath applied CBZ (0.01-1 mM) exerted a concentration-dependent decrease in the amplitude of the field excitatory postsynaptic potentials with an IC(50) of approximately 194.3 microM. When OXC was used at the same concentrations, the concentration-response curve was shifted to the right (IC(50) of approximately 711.07 microM). In addition, we demonstrated that CBZ and OXC reduced, to a different extent, both evoked excitatory postsynaptic currents and NMDA-, AMPA-, and KA-mediated inward currents, CBZ being more potent than OXC. These data highlight distinct presynaptic and postsynaptic sites of action for both compounds and suggest that CBZ, by markedly depressing postsynaptic ionotropic glutamate receptors-mediated responses, may produce more severe cognitive and memory impairment. Thus, we assume that relatively high doses of OXC could be better tolerated than therapeutically equivalent doses of CBZ, justifying the preferential use of OXC as first-line treatment in the therapy of neurological and psychiatric disorders, particularly when compared with CBZ.

UI MeSH Term Description Entries
D009435 Synaptic Transmission The communication from a NEURON to a target (neuron, muscle, or secretory cell) across a SYNAPSE. In chemical synaptic transmission, the presynaptic neuron releases a NEUROTRANSMITTER that diffuses across the synaptic cleft and binds to specific synaptic receptors, activating them. The activated receptors modulate specific ion channels and/or second-messenger systems in the postsynaptic cell. In electrical synaptic transmission, electrical signals are communicated as an ionic current flow across ELECTRICAL SYNAPSES. Neural Transmission,Neurotransmission,Transmission, Neural,Transmission, Synaptic
D002220 Carbamazepine A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties. Amizepine,Carbamazepine Acetate,Carbamazepine Anhydrous,Carbamazepine Dihydrate,Carbamazepine Hydrochloride,Carbamazepine L-Tartrate (4:1),Carbamazepine Phosphate,Carbamazepine Sulfate (2:1),Carbazepin,Epitol,Finlepsin,Neurotol,Tegretol
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006624 Hippocampus A curved elevation of GRAY MATTER extending the entire length of the floor of the TEMPORAL HORN of the LATERAL VENTRICLE (see also TEMPORAL LOBE). The hippocampus proper, subiculum, and DENTATE GYRUS constitute the hippocampal formation. Sometimes authors include the ENTORHINAL CORTEX in the hippocampal formation. Ammon Horn,Cornu Ammonis,Hippocampal Formation,Subiculum,Ammon's Horn,Hippocampus Proper,Ammons Horn,Formation, Hippocampal,Formations, Hippocampal,Hippocampal Formations,Hippocampus Propers,Horn, Ammon,Horn, Ammon's,Proper, Hippocampus,Propers, Hippocampus,Subiculums
D000078330 Oxcarbazepine A carbamazepine derivative that acts as a voltage-gated sodium channel blocker. It is used for the treatment of PARTIAL SEIZURES with or without secondary generalization. It is also an inducer of CYTOCHROME P-450 CYP3A4. 10,11-Dihydro-10-oxo-5H-dibenz(b,f)azepine-5-carboxamide,GP 47680,Timox,Trileptal
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D019706 Excitatory Postsynaptic Potentials Depolarization of membrane potentials at the SYNAPTIC MEMBRANES of target neurons during neurotransmission. Excitatory postsynaptic potentials can singly or in summation reach the trigger threshold for ACTION POTENTIALS. EPSP,End Plate Potentials,Excitatory Postsynaptic Currents,Current, Excitatory Postsynaptic,Currents, Excitatory Postsynaptic,End Plate Potential,Excitatory Postsynaptic Current,Excitatory Postsynaptic Potential,Plate Potential, End,Plate Potentials, End,Postsynaptic Current, Excitatory,Postsynaptic Currents, Excitatory,Postsynaptic Potential, Excitatory,Postsynaptic Potentials, Excitatory,Potential, End Plate,Potential, Excitatory Postsynaptic,Potentials, End Plate,Potentials, Excitatory Postsynaptic

Related Publications

Michela Giustizieri, and Marta Armogida, and Nicola Berretta, and Mauro Federici, and Silvia Piccirilli, and Nicola B Mercuri, and Robert Nistico
July 2015, The Journal of neuroscience : the official journal of the Society for Neuroscience,
Michela Giustizieri, and Marta Armogida, and Nicola Berretta, and Mauro Federici, and Silvia Piccirilli, and Nicola B Mercuri, and Robert Nistico
May 1992, Acta anaesthesiologica Scandinavica,
Michela Giustizieri, and Marta Armogida, and Nicola Berretta, and Mauro Federici, and Silvia Piccirilli, and Nicola B Mercuri, and Robert Nistico
September 1985, Journal of neurophysiology,
Michela Giustizieri, and Marta Armogida, and Nicola Berretta, and Mauro Federici, and Silvia Piccirilli, and Nicola B Mercuri, and Robert Nistico
September 2006, Brain research,
Michela Giustizieri, and Marta Armogida, and Nicola Berretta, and Mauro Federici, and Silvia Piccirilli, and Nicola B Mercuri, and Robert Nistico
May 2006, Journal of neurophysiology,
Michela Giustizieri, and Marta Armogida, and Nicola Berretta, and Mauro Federici, and Silvia Piccirilli, and Nicola B Mercuri, and Robert Nistico
July 1998, British journal of pharmacology,
Michela Giustizieri, and Marta Armogida, and Nicola Berretta, and Mauro Federici, and Silvia Piccirilli, and Nicola B Mercuri, and Robert Nistico
August 2003, Epilepsy research,
Michela Giustizieri, and Marta Armogida, and Nicola Berretta, and Mauro Federici, and Silvia Piccirilli, and Nicola B Mercuri, and Robert Nistico
July 2019, Neuroscience,
Michela Giustizieri, and Marta Armogida, and Nicola Berretta, and Mauro Federici, and Silvia Piccirilli, and Nicola B Mercuri, and Robert Nistico
October 1989, Anesthesiology,
Michela Giustizieri, and Marta Armogida, and Nicola Berretta, and Mauro Federici, and Silvia Piccirilli, and Nicola B Mercuri, and Robert Nistico
November 1981, Brain research,
Copied contents to your clipboard!